SG11201507380PA - Novel inhibitor compounds of phosphodiesterase type 10a - Google Patents
Novel inhibitor compounds of phosphodiesterase type 10aInfo
- Publication number
- SG11201507380PA SG11201507380PA SG11201507380PA SG11201507380PA SG11201507380PA SG 11201507380P A SG11201507380P A SG 11201507380PA SG 11201507380P A SG11201507380P A SG 11201507380PA SG 11201507380P A SG11201507380P A SG 11201507380PA SG 11201507380P A SG11201507380P A SG 11201507380PA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitor compounds
- phosphodiesterase type
- novel inhibitor
- novel
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779141P | 2013-03-13 | 2013-03-13 | |
| PCT/EP2014/054810 WO2014140086A1 (en) | 2013-03-13 | 2014-03-12 | Novel inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507380PA true SG11201507380PA (en) | 2015-10-29 |
Family
ID=50241454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507380PA SG11201507380PA (en) | 2013-03-13 | 2014-03-12 | Novel inhibitor compounds of phosphodiesterase type 10a |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9200005B2 (ko) |
| EP (1) | EP2970328B1 (ko) |
| JP (1) | JP2016510786A (ko) |
| KR (1) | KR20150127724A (ko) |
| CN (1) | CN105358561A (ko) |
| AR (1) | AR095267A1 (ko) |
| AU (1) | AU2014230825A1 (ko) |
| BR (1) | BR112015022094A2 (ko) |
| CA (1) | CA2902654A1 (ko) |
| CL (1) | CL2015002545A1 (ko) |
| CR (1) | CR20150496A (ko) |
| DO (1) | DOP2015000214A (ko) |
| HK (1) | HK1219273A1 (ko) |
| IL (1) | IL240593A0 (ko) |
| MX (1) | MX2015012389A (ko) |
| PE (1) | PE20160040A1 (ko) |
| PH (1) | PH12015501962A1 (ko) |
| RU (1) | RU2015143536A (ko) |
| SG (1) | SG11201507380PA (ko) |
| TW (1) | TW201441230A (ko) |
| UY (1) | UY35393A (ko) |
| WO (1) | WO2014140086A1 (ko) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6814730B2 (ja) | 2014-09-05 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| JP6767969B2 (ja) | 2014-09-05 | 2020-10-14 | ジェネンテック， インコーポレイテッド | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 |
| CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
| CA3067591A1 (en) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| CN115838364A (zh) * | 2022-12-20 | 2023-03-24 | 河南沁朋科技有限公司 | 一种3,3-双噻吩的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284079A (zh) | 1997-12-05 | 2001-02-14 | 阿斯特拉曾尼卡英国有限公司 | 新化合物 |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| MX2007002592A (es) | 2004-09-03 | 2007-10-10 | Memory Pharm Corp | Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos. |
| US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| JP2009524637A (ja) | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| CA2643983A1 (en) | 2006-02-21 | 2007-08-30 | Amgen, Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009527560A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体 |
| WO2007096743A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| WO2007100880A1 (en) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| EP1996574A1 (en) | 2006-03-08 | 2008-12-03 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| CN101495476A (zh) | 2006-07-10 | 2009-07-29 | H.隆德贝克有限公司 | 6,7-二烷氧基喹唑啉、6,7-二烷氧基酞嗪和6,7-二烷氧基异喹啉的(3-芳基-哌嗪-1-基)、(2-芳基-吗啉-4-基)和(2-芳基-硫代吗啉-4-基)衍生物 |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090062291A1 (en) | 2007-08-22 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| AU2008329775A1 (en) | 2007-11-30 | 2009-06-04 | Biotie Therapies Gmbh | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2471791B1 (en) * | 2009-08-26 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| US20130203756A1 (en) | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
-
2014
- 2014-02-25 US US14/189,961 patent/US9200005B2/en not_active Expired - Fee Related
- 2014-03-12 UY UY0001035393A patent/UY35393A/es not_active Application Discontinuation
- 2014-03-12 JP JP2015562117A patent/JP2016510786A/ja active Pending
- 2014-03-12 MX MX2015012389A patent/MX2015012389A/es unknown
- 2014-03-12 CN CN201480014146.XA patent/CN105358561A/zh active Pending
- 2014-03-12 EP EP14709320.7A patent/EP2970328B1/en not_active Not-in-force
- 2014-03-12 BR BR112015022094A patent/BR112015022094A2/pt not_active IP Right Cessation
- 2014-03-12 AU AU2014230825A patent/AU2014230825A1/en not_active Abandoned
- 2014-03-12 PE PE2015001893A patent/PE20160040A1/es not_active Application Discontinuation
- 2014-03-12 WO PCT/EP2014/054810 patent/WO2014140086A1/en active Application Filing
- 2014-03-12 KR KR1020157029132A patent/KR20150127724A/ko not_active Application Discontinuation
- 2014-03-12 SG SG11201507380PA patent/SG11201507380PA/en unknown
- 2014-03-12 AR ARP140100879A patent/AR095267A1/es unknown
- 2014-03-12 CA CA2902654A patent/CA2902654A1/en not_active Abandoned
- 2014-03-12 TW TW103108560A patent/TW201441230A/zh unknown
- 2014-03-12 RU RU2015143536A patent/RU2015143536A/ru unknown
-
2015
- 2015-08-16 IL IL240593A patent/IL240593A0/en unknown
- 2015-09-03 DO DO2015000214A patent/DOP2015000214A/es unknown
- 2015-09-04 PH PH12015501962A patent/PH12015501962A1/en unknown
- 2015-09-09 CL CL2015002545A patent/CL2015002545A1/es unknown
- 2015-09-16 CR CR20150496A patent/CR20150496A/es unknown
-
2016
- 2016-06-22 HK HK16107260.0A patent/HK1219273A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR095267A1 (es) | 2015-09-30 |
| CA2902654A1 (en) | 2014-09-18 |
| CR20150496A (es) | 2016-02-19 |
| US9200005B2 (en) | 2015-12-01 |
| IL240593A0 (en) | 2015-09-24 |
| WO2014140086A1 (en) | 2014-09-18 |
| US20140275069A1 (en) | 2014-09-18 |
| BR112015022094A2 (pt) | 2018-06-12 |
| TW201441230A (zh) | 2014-11-01 |
| CN105358561A (zh) | 2016-02-24 |
| HK1219273A1 (zh) | 2017-03-31 |
| PE20160040A1 (es) | 2016-02-11 |
| RU2015143536A (ru) | 2017-04-18 |
| KR20150127724A (ko) | 2015-11-17 |
| UY35393A (es) | 2014-10-31 |
| CL2015002545A1 (es) | 2016-07-22 |
| AU2014230825A1 (en) | 2015-09-03 |
| EP2970328A1 (en) | 2016-01-20 |
| JP2016510786A (ja) | 2016-04-11 |
| EP2970328B1 (en) | 2017-04-26 |
| DOP2015000214A (es) | 2015-12-31 |
| PH12015501962A1 (en) | 2016-01-11 |
| MX2015012389A (es) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279682A (en) | Benzoquinolone compounds as VMAT2 inhibitors | |
| HK1222390A1 (zh) | 抑制劑的多晶型 | |
| HK1222387A1 (zh) | 作為 抑制劑的芳基吡咯並吡啶衍生的化合物 | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| HK1216531A1 (zh) | 新的抑制劑 | |
| EP2968204A4 (en) | TREATMENT WITH A PHOSPHODIESTERASE HEMMER | |
| GB201317609D0 (en) | Inhibitor compounds | |
| HK1219273A1 (zh) | 磷酸二酯酶 型的新型抑制劑化合物 | |
| HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
| EP3020718A4 (en) | NOVEL PDE4 INHIBITOR | |
| HK1221645A1 (zh) | 的苯並喹啉抑制劑 | |
| IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
| HK1206728A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
| ZA201507100B (en) | Synthesis of bace1 inhibitors | |
| HK1211581A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a 10a | |
| HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 | |
| EP2959896A4 (en) | INHIBITOR OF PHOSPHORYLATION OF PROTEIN T | |
| HK1211284A1 (en) | Inhibitor compounds of phosphodiesterase type 10a 10a | |
| GB201321328D0 (en) | Inhibitor compounds | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors |